Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1501032 | 0.98 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1500905 | 0.93 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1501416 | 0.92 | PLA2G4A (0.86) | PLA2G4A | |
| SCHEMBL1500794 | 0.91 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1501206 | 0.91 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1500822 | 0.91 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1500986 | 0.91 | PLA2G4A (0.88) | PLA2G4A | |
| SCHEMBL1501208 | 0.90 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1500994 | 0.90 | PLA2G4A (1.00) | PLA2G4A | |
| SCHEMBL1500868 | 0.89 | PLA2G4A (1.00) | PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4657605-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| US-7713964-B2 | Methods for treating asthmatic conditions | WYETH LLC (US) | 2010-05-11 | — | — | US | claimed |
| US-7605156-B2 | Methods for the use of inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2009-10-20 | — | — | US | claimed |
| EP-1892239-A1 | Inhibitors of cytosolic phospholipase A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | claimed |
| EP-1451154-B1 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH CORP (US) | 2008-01-16 | — | — | EP | claimed |
| US-20080009485-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis | WYETH (US) | 2008-01-10 | — | — | US | claimed |
| US-7101875-B2 | Methods for treating arthritic disorders | WYETH (US) | 2006-09-05 | — | — | US | claimed |
| JP-2005515997-A | — | — | 2005-06-02 | — | — | JP | claimed |
| US-6797708-B2 | ENZYME INHIBITORS SUCH AS 4-(2-(1-BENZHYDRYL-2-(2-((BENZYL-SULFONYL)AMINO)ETHYL)-5-CHLORO-1H-INDOL-3 -YL)ETHOXY) BENZOIC ACID, USED AS ANALGESICS OR ANTIINFLAMMATORY AGENTS | WYETH | 2004-09-28 | — | — | US | claimed |
| EP-1451154-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth (US) | 2004-09-01 | — | — | EP | claimed |
| US-20030166649-A1 | Methods for treating arthritic disorders | WYETH | 2003-09-04 | — | — | US | claimed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | claimed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | claimed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | claimed |
| EP-1892239-B1 | Inhibitors of cytosolic phospholipase A2 | WYETH LLC (US) | 2013-02-20 | — | — | EP | disclosed |
| US-7906548-B2 | Methods for the use of inhibitors of cytosolic phospholipase A2 | WYETH LLC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7713964-B2 | Methods for treating asthmatic conditions | WYETH LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009485-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis | PLA2G12A, PLA2G1B, PLA2G5 | PLA2G4A 5/4885 |
| US-20030166649-A1 | Methods for treating arthritic disorders | PLA2G12A, PLA2G4A, PLA2G4B | PLA2G4A 2/4885 |
| US-20030149029-A1 | Methods for treating asthmatic conditions | PLA2G4A, PLA2G4B, PLA2G1B | PLA2G4A 1/4885 |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G4C | PLA2G4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.